In this week’s issue of The Savvy Diabetic:
Police Tussle With Diabetes Experts at ADA Meeting
Insulet launches algorithm improvements for Omnipod 5 AID system
Four New Sensors in One Month, report by Diabetotech.com
MIT, Apollon say needle-free CGM matched accuracy of leading sensors
Did Dexcom Just Admit They Need To Do Better?
The Libre Duo. A platform prototype for care from hospital to home?
The science around GLP-1 drugs and cancer is getting more interesting
Ranking high blood pressure drug combinations: most to least tolerated
Helpful Tools for the Type 1 Diabetes Journey from BlueCircleHealth.org
News from T1Dto100
Video: Managing Steroids with T1D Webinar with Carolyn Robertson, 14 May 2026
Dr. Medha Munshi’s Book Receives IBPA Silver Award!
Police Tussle With Diabetes Experts at ADA Meeting by Kristina Fiore for MedPageToday.com, 5 June 2026.
Members of the American Diabetes Association (ADA) were escorted by police out of the convention center in New Orleans during the organization’s annual meeting on Friday as they handed out copies of an editorial criticizing the Trump administration’s changes to U.S. biomedical research.
Among them was Steven Kahn, MBChB, the lead author of the editorial, which published online in late April in the organization’s flagship journal, Diabetes Care. Kahn is also the editor in chief of the journal.Kahn, Aaron Kelly, PhD, past ADA president Desmond Schatz, MD, Justin Ryder, PhD, Irl Hirsch, MD, and at least one other member were handing out printed copies of the editorial outside of a keynote speech given by an NIH official. NIH Director Jay Bhattacharya, MD, PhD, was supposed to give the talk, but pulled out at the last minute,
ADA’s media team confirmed that five registrants were removed for violating code of conduct rules that they agreed to when registering for the meeting. “These attendees were escorted out by our onsite event security because they demonstrated behavior not consistent with this code of conduct,” the media team said in a statement. “They were respectfully given the opportunity to cease this behavior and chose not to which is why they were escorted out.”
Kahn said he has written to ADA to be allowed to re-enter the meeting as he is due to give a talk, present a poster, and chair a session.
The editorial, which was co-authored by John Buse, MD, PhD, and others, is titled: “Misguided Brushes of a Pen Continue to Dismantle and Destroy Biomedical Research in the United States: We Can No Longer Afford Complacency and Fear. We Must All Act Now!” It criticizes the Trump administration’s requested 2027 budget that seeks a $5 billion reduction to NIH, along with the numerous changes to HHS and the NIH made since January 2025. It also details the many impacts to diabetes research funding since that time.
“There is an urgent need for all of us to bring attention to these destructive processes and halt them before the ongoing and proposed dissolution and destruction of critical components of our biomedical research infrastructure are completed. Enough is enough!” the editorial stated. “It is no longer enough to stand idly by or work behind the scenes with lawmakers. Moreover, it is no longer appropriate to fret about political backlash,” it continued. “Now is the time to recognize and fight to reverse the spiraling fall of the United States of America’s status as the foremost nation in health care innovation.”
Read more:
Insulet launches algorithm improvements for Omnipod 5 AID system in US by Salong Debbarma for MedicalDevice-Network.com, 4 June 2026.
Insulet has begun distributing an updated version of its Omnipod 5 automated insulin delivery (AID) system across the US, following 510(k) clearance from the US Food and Drug Administration (FDA) in December 2025. The latest software changes are accessible to both new and existing users nationwide, accompanied by Omnipod 5’s new capacity to work with Abbott’s FreeStyle Libre 3 Plus sensor. This update allows additional flexibility for individuals managing diabetes. Insulet has incorporated a new algorithm into Omnipod 5, marking the system’s most significant change since its introduction in 2022.
The update offers healthcare professionals and patients six target glucose options ranging from 100mg/dL to 150mg/dL, including a new 100mg/dL target glucose choice. The algorithm also seeks to minimise breaks in Automated Mode operation, even if users experience prolonged elevated glucose readings. Beyond the algorithm advancement, Omnipod 5’s compatibility now extends to Abbott’s Libre 3 Plus sensor for users in the US. This integration allows caregivers to monitor patient information through Abbott’s LibreLinkup app. Insulet also intends to broaden this compatibility to other countries later this year.
Read more: Insulet launches algorithm improvements for Omnipod 5 AID system in US
Four New Sensors in One Month by Diabetotech.com, 4 June 2026.
May 2026 was one of the busiest months in the history of continuous glucose monitoring. Within less than 30 days, four new sensor platforms were launched, previewed or received regulatory approval across three continents. At the same time, several companies unveiled plans to move beyond glucose and continuously measure ketones, potassium and lactate.
Perhaps the real story is about a rapidly maturing market. As continuous glucose monitoring becomes increasingly established, manufacturers are looking for new ways to differentiate themselves. Some are adding biomarkers. Others are targeting new patient populations. Still others are focusing on manufacturing scale and lower-cost access.
Belvix Diagnostics 365+ sensor: At DTechCon 2026 in Mumbai, Belvix Diagnostics India introduced the CGMs365+ sensor, based on technology developed by Chinese manufacturer Eaglenos Sciences. Eaglenos received Chinese NMPA approval in 2025 and is now rapidly expanding internationally. The company is already promoting the same technology under different brand names in several regions, including Poland, and announced its entry into Brazil and Latin America this month. Through its partnership with Belvix, local manufacturing will also start in India. The sensor specifications are competitive: 15-day wear time; Factory calibration; Measurements every 3 minutes; All-in-one sensor and transmitter; Claimed MARD of 8.76%
Although a MARD of 8.76% was quoted, supporting peer-reviewed accuracy data were not publicly available at the time of writing. As always, independent validation studies will ultimately determine how the sensor performs in clinical practice.
2. Dexcom Flex: A New Sensor or a New Strategy?
Technically, Flex is not a revolutionary product. Strategically, however, it may be one of the most interesting launches of the year. Dexcom Flex is intended for adults with type 2 diabetes who are not on intensive insulin therapy, including people treated with basal insulin, oral medication or GLP-1 receptor agonists. This reflects a broader shift happening throughout diabetes care.
3. Libre Duo: Potentially Important, but We Are Still Learning How to Use Ketones.
Four years after it was first announced, Abbott finally received CE Mark approval for Libre Duo and Libre Duo 10 Day. The sensor continuously measures both glucose and ketones from a single wearable device. Several automated insulin delivery manufacturers—including Tandem, Beta Bionics, Sequel, Ypsomed and MiniMed—have already announced planned integrations. Of all the announcements this month, Libre Duo may ultimately have the biggest clinical impact because ketones are directly linked to one of the most feared acute complications in diabetes: diabetic ketoacidosis.
3. Dexcom G8: Evolution Rather Than Revolution
Dexcom revealed the first official image and specifications of the Dexcom G8. Expected launch is late 2027 or early 2028. The improvements are meaningful: 15-day wear time; Approximately 50% smaller design; Adaptive algorithm designed to reduce outlier readings; Future multi-analyte capabilities
A few years ago, a smaller sensor with longer wear time would have fundamentally changed the competitive landscape. Today, many manufacturers are already moving toward similar specifications. By the time G8 launches, it will enter a market filled with highly accurate, small, long-lasting sensors. Dexcom has openly discussed future ketone and potassium monitoring capabilities. Potassium monitoring is particularly intriguing. Many people with diabetes have chronic kidney disease and use medications that influence potassium balance. Hyperkalemia can be dangerous and is currently detected only through blood testing.
The Multi-Analyte Race Has Started: Abbott is betting on ketones. Dexcom is exploring ketones and potassium. Eaglenos is working on lactate. SiBionics already markets a continuous ketone monitor and is developing an integrated glucose-ketone platform.
The direction of travel is clear. Future sensors will measure more than glucose. The question is whether measuring more automatically creates more value. Perhaps the Real Story Is Price. Looking across all announcements this month, one conclusion stands out. The most important development may not be a new biomarker. It may be the growing number of competitors. And mature markets eventually become competitive on price.
Read more: Four New Sensors in One Month
MIT, Apollon say needle-free CGM matched accuracy of leading sensors in study by Sean Whooley for DrugDeliveryBusiness.com, 1 June 2026.
Apollon and an MIT lab today shared clinical findings demonstrating the accuracy of their non-invasive continuous glucose monitor (CGM) device. Boston-based Apollon and MIT’s Laser Biomedical Research Center (LBRC) published their findings from the peer-reviewed clinical study in the Journal of Diabetes Science and Technology. Outcomes demonstrated that a compact, non-invasive CGM device based on band-pass Raman spectroscopy achieves clinical accuracy statistically comparable to needle-based leading CGMs from Abbott and Dexcom. However, this device features no skin insertion, no adhesive patch and no consumables.
The shoebox-sized device probes glucose molecules in the interstitial fluid transdermally using three ultra-narrow Raman bands. It eliminates the need for bulky spectrometers, enabling a compact, low-cost design without sacrificing sensitivity. Unlike conventional CGMs that require constant sensor replacement, Apollon’s approach requires no consumables over the device lifetime.
Findings included a mean absolute relative difference (MARD) of 11.3. This proved “statistically indistinguishable” from the latest-generation Abbott FreeStyle Libre 3 and Dexcom G7 CGMs, Apollon said. Building on its findings, Apollon now plans a clinical feasibility study at Boston Medical Center (BMC) in the second half of 2026. It expects the study to expand validation to a broader population of patients with diabetes and advance its FDA pathway.
Did Dexcom Just Admit They Need To Do Better? with Dr. David Ahn as @AhnCall on Instagram.com, 2 June 2026.
@dexcom just released the inaugural report from the newly formed Customer Advisory Council. When people think of exciting announcements from diabetes companies, they usually think about new hardware or features, but this report might be even more important for Dexcom because it might signal a vibe shift and re-focusing on the people who matter most: people with diabetes. In this report, Dexcom openly acknowledged concerns around product reliability, customer support, replacement policies, communication, and trust. As someone who serves on the Dexcom Customer Advisory Council, I found the report incredibly refreshing.
No company is perfect. Trust isn’t built by pretending problems don’t exist. Trust is built by listening, acknowledging challenges, communicating openly, and following through on commitments. Of course, transparency is only the first step. Rebuilding trust takes time, and ultimately actions speak louder than words. But if you’re going to earn trust, having an honest conversation is a pretty good place to start.
And it’s always important to note the importance of healthy competition in the CGM space, brought by companies like Abbott and Eversense. Competition increases innovation, hopefully lowers cost, and in the case of this report, increases transparency and humility.
What do you think? Is transparency from healthcare companies something you value? Is this just hot air or a real shift?
Want to know who’s on the Council? It’s interesting: Dexcom Customer Advisory Council
The Libre Duo. A platform prototype to move care from the hospital to the home? by Tim Street for Diabettech.com, 1 June 2026.
Abbott has put glucose and ketones on the same wearable, and the launch coverage is all about DKA. Worth having if you’re on a pump, which is fine as far as it goes, but it misses the bit that makes this interesting. Because if you look at what Abbott has actually built across its other divisions, and what they’ve patented alongside it, the Libre Duo doesn’t really look like a ketone sensor. It looks like the first visible piece of an infrastructure designed to move chronic disease care out of outpatients and into the home.
The Libre Duo is a dual Glucose and beta-hydroxybutyrate (ketones, to you, me and everyone else) sensor, which will be available in two forms: A 15 day adult version and a 10 day version that can be used with kids aged 2 and over. According to the press release, industry partners that are already lined up to use it include Tandem, Betabionics, CamDiab and Ypsomed. It adheres to the familiar Libre design and application process, so allows existing users continuity if they choose to adopt it. The ketone alert thresholds Abbott has mentioned align with what those with type 1 diabetes should already be familiar with. Below 0.6 mmol/l is unremarkable, 1.5 and up warrants attention, while above 3.0mmol/l is considered serious. As with existing Libre products, data is delivered every minute.
Ketones use a related approach but with a more involved enzymatic cascade. Here we have two enzymes working in sequence on one electrode, both held in place by covalent bonding to a polymer matrix, with albumin in there as a stabiliser. That’s quite a bit more complicated than the basic glucose sensor. What’s clear is that BHB sensing is much harder than glucose. DKA is common, and when it does occur, expensive to treat and potentially deadly. A glucose-only CGM can’t see it coming reliably because glucose and ketones don’t always move together. If we can get an earlier warning, then lives can be made easier and healthcare costs reduced. US DKA costs run into the billions a year and DKA is a leading cause of death in under-24s with diabetes.
So the sensor is brilliant for pump-user device-failure DKA, and that’s a real population worth protecting. It’s not very useful for socio-economic driven DKA that does most of the harm. It doesn’t change the game on DKA in aggregate. It changes it for the subset of users it reaches, which is roughly the opposite of the high-risk group.
Read more: The Libre Duo. A platform prototype to move care from the hospital to the home?
The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting by Ariana Eunjung Cha & Christopher Rowland for WashingtonPost.com, 3 June 2026.
Now a growing body of research is raising another possibility: that these drugs may help protect against cancer. At this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago, more than 40 studies, abstracts, oral presentations and poster presentations examined the relationship between GLP-1-based drugs and cancer. The results were strikingly consistent. Taken together, they suggest that people taking medications such as Ozempic, Wegovy and Mounjaro may develop certain cancers at lower rates than comparable patients who are not taking the drugs — and that those already diagnosed may experience a slower decline and better outcomes.
For oncologists, the accumulation of evidence is hard to dismiss. The findings are “super promising,” said Mark Orland, a cancer researcher at the Cleveland Clinic. “We’re really excited to be on the forefront of looking at the effects of these drugs.”
The studies spanned many of the 13 cancers associated with obesity. Among the most prominent is an analysis from the University of Pennsylvania presented on Tuesday. It looked at data from more than 100,000 women and found lower rates of breast cancer among those taking the drugs. Another followed more than 10,000 patients and found that those taking the medications were significantly less likely to progress to metastatic disease across four solid tumors.
Also drawing attention were findings related to lung cancer — because it is not generally associated with weight — as well as a few studies hinting that GLP-1s could enhance the effectiveness of cancer treatments. Those findings have fueled a particularly intriguing possibility: that GLP-1s may be acting independently of weight loss — by reducing inflammation, altering metabolic pathways involved in cancer development or perhaps even slowing tumor growth itself.
None of this proves that GLP-1s prevent cancer, and doctors said the evidence is not yet strong enough to recommend prescribing the drugs for that purpose.
Read more: The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting
A recent study involving 159,362 participants analyzed which blood pressure drugs, or combinations of drugs, were most likely to cause side effects and which were easiest for patients to continue.
Angiotensin II receptor blockers (ARBs) came at the top for having the lowest rates of patients stopping treatment, with fewer treatment withdrawals than even a placebo. Among combinations, the pairing of an ARB with a calcium channel blocker (CCB) was the best tolerated. CCB alone, on the other hand, was significantly more likely to cause side effects, leading to higher discontinuation of medication.
The findings are published in JAMA.
Read more: Ranking high blood pressure drug combinations from most to least tolerated
A Useful Resource: Helpful Tools for the Type 1 Diabetes Journey from BlueCircleHealth.org.
Explore trusted tips, tools, and guides designed to make life with type 1 diabetes a little easier — and help you reach your diabetes goals with confidence. Topics include:
Resources for People Living with T1D
Helpful national nonprofits focused on T1D
Resources for Healthcare Professionals
Recursos en Espanol
Read more: Helpful Tools for the Type 1 Diabetes Journey
News from T1Dto100
Webinar: Managing Steroids with T1D — with Carolyn Robertson, APRN, MSN, CDCES, recorded 14 May 2026.
A conversation with Carolyn Robertson, APRN, MSN, CDCES, on managing blood glucose when steroids are part of the picture. Whether you’re preparing for a procedure, recovering from one, or navigating steroids for another medical reason, this talk will cover what to expect before, during, and after — and how to adjust your T1D management accordingly.Carolyn Robertson is a Certified Diabetes Care and Education Specialist. She holds board certifications as an Adult Clinical Nurse Specialist (BC-ACNS) and in Advanced Diabetes Management (BC-ADM). She has several decades of experience providing care solely to individuals with Type 1 Diabetes providing personalized treatment and management, assistance with psychosocial issues, and lifestyle counseling assistance. Ms. Robertson was a pioneer in the intensive management of diabetic pregnancies as well as an early pioneer in insulin pump therapy. Ms. Robertson received her Masters of Science degree in Nursing from Hunter College of the City University of New York.
Ms. Robertson has opened two diabetes university-based diabetes centers in Manhattan, and served as Associate Director at each of those centers. Additionally, she was the program director at the Gonda Diabetes Center at UCLA in Los Angeles and was responsible for creating their type 1 program.
Ms. Robertson has been a local board member of both the Juvenile Diabetes Foundation Research International and the American Diabetes Association. She has published widely in peer-reviewed journals, trade journals, books, and newsletters, as well as on the Internet. She has been a speaker nationally and internationally regarding diabetes management and the impact of technology on diabetes care and outcomes.
Subscribe to our YouTube for more webinar recordings: https://youtube.com/@t1dto100
____________________________________________________________
Dr. Medha Munshi’s Book Receives IBPA SIlver Award!
Aging Well with Diabetes is written by Medha Munshi, MD and Sheri Colberg, PhD … a 10-Point Action Plan for Older Adults, published by Johns Hopkins University Press. From Medha Munshi, Professor of Medicine, Harvard Medical School, Endocrinologist/Geriatrician with Joslin Diabetes Center and founder, International Geriatric Diabetes Society … and, with T1Dto100, on our advisory panel and founding Board member.
Very excited to receive the news that our book “Aging Well with Diabetes” has been named IBPA Silver Award Winner! Thank you Sheri for this wonderul journey of writing this book. This award is just a Cherry on the top!!!
Dr. Munshi presented at ADA in New Orleans … to an only half-full room … with more attendees than last year. This is an important topic: Technology for us aging T1Ds. How can we continue to use our technology as we age.
Our work is cut out for us … we need MORE recognition and many more seats at the table for Aging and Type 1 diabetes! We are the fastest growing demographics, with over 50 year olds making up the MAJORITY of T1Ds. Guess we need to get louder and more persistent with our advocacy!!!
Feel free to join us at Facebook T1Dto100 … learn what we are working on, join our efforts, share our events and knowledge in your personal communities and among your healthcare providers!
